WNT5A is a member of the Wnt family of secreted glycoproteins that function as key signaling molecules during embryonic development, tissue homeostasis, and adult tissue maintenance[1]. WNT5A belongs to the "non-canonical" subclass of Wnt ligands that primarily signal through β-catenin-independent pathways.
In the central nervous system, WNT5A plays crucial roles in neurodevelopment, synaptic formation and plasticity, neurogenesis, and the regulation of neuronal survival[@angers2010]. Importantly, WNT5A dysregulation has been implicated in Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS)[2][3].
| Property | Value |
|---|---|
| Protein Name | WNT5A |
| Gene | WNT5A |
| UniProt ID | P41221 |
| Protein Length | 380 amino acids |
| Molecular Weight | ~40 kDa |
| Subcellular Localization | Secreted, cell surface |
| Protein Family | Wnt family |
| Associated Diseases | AD, PD, ALS |
WNT5A primarily signals through β-catenin-independent pathways:
1. Planar Cell Polarity (PCP) Pathway:
2. Wnt/Ca²⁺ Pathway:
Multiple studies have documented WNT5A alterations in AD brains[2:1]:
WNT5A promotes neuroinflammation and affects tau phosphorylation through modulation of tau kinases (GSK3β, CDK5).
Targeting WNT5A signaling in AD represents a promising approach[4]:
Clinical and experimental studies have implicated WNT5A in PD[3:1]:
WNT5A dysregulation has been reported in ALS[5]:
WNT5A is a multifunctional Wnt ligand that plays critical roles in neurodevelopment, synaptic plasticity, and adult brain function. Its signaling through non-canonical pathways modulates neuronal differentiation, synapse formation, and neuroprotection. In AD, PD, and ALS, WNT5A expression and signaling are dysregulated, contributing to disease pathogenesis.
Clevers H, et al. Wnt/β-catenin signaling and disease. Cell. 2012. ↩︎
Inestrosa NC, et al. Wnt signaling in Alzheimer's disease. Neurobiology of Aging. 2013. ↩︎ ↩︎
Patrono C, et al. Wnt5a in Parkinson's disease. Movement Disorders. 2019. ↩︎ ↩︎
Wang J, et al. Wnt5a in Alzheimer's disease therapy. Journal of Alzheimer's Disease. 2016. ↩︎
Garrido JL, et al. Wnt5a in ALS and motor neuron disease. Experimental Neurology. 2019. ↩︎